The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes.

Shah, Rajanya D

The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes. [electronic resource] - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2005 - 41-50 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1015-8987

10.1159/000083637 doi


Animals
Animals, Newborn
Calcium--metabolism
Calcium Signaling--drug effects
Calcium-Transporting ATPases--metabolism
Cells, Cultured
Enzyme Induction--drug effects
Heart Ventricles--drug effects
Hypoglycemic Agents--pharmacology
Interleukin-6--metabolism
Lipopolysaccharides--pharmacology
Luciferases--metabolism
Muscle Cells--cytology
NF-kappa B--metabolism
Rats
Rats, Sprague-Dawley
Rosiglitazone
Sarcoplasmic Reticulum Calcium-Transporting ATPases
Thiazolidinediones--pharmacology
Transcription Factor RelA
Transcription, Genetic--drug effects
Tumor Necrosis Factor-alpha--pharmacology
beta-Galactosidase--metabolism